Nath Bio-Genes Posts Strong Growth in Q1FY27 and Maintains Stable Profitability in FY26
Nath Bio-Genes (India) Limited reported its financial results for the period ended June 30, 2026. The company demonstrated growth across various segments while maintaining a strong balance sheet.The organization highlighted its comprehensive operational infrastructure, which includes a network of approximately 20,000 distributors and dealers, 17 branch offices, 10 processing plants, and warehouses spread across 23 states of India. Nath Bio-Genes emphasizes building an unparalleled supply chain through symbiotic relationships with its production growers and organizers.
Business and R&D Focus
Nath Bio-Genes focuses on developing tailored products by conducting deep market research to understand key farmer requirements. The company develops products suited for diverse agricultural climatic conditions, concentrating on disease and pest resistance to ensure higher yields.The R&D department is staffed by experienced scientists and experts and maintains a large and diverse collection of germplasm. Innovation centers recognized by DSIR are utilized, and the company has cold storage facilities, warehouses, and conditioning godowns with a capacity of 25,000 MT.
Key business highlights for the period include stable volume and value in Cotton, Bajra, and Jowar. Maize recorded notable growth, showing a 44% increase in volume and 59% growth in value. Paddy also showed robust growth, achieving a 19% increase in volume and 34% growth in value, driven by premium-value products. The PNS segment experienced an 18% growth in volume and 25% growth in value.
Q1FY27 Income Statement Details
The company's financial performance for Q1FY27 is detailed below:| Particulars (INR Mn) | Q1FY27 | Q1FY26 | %Change(YoY) | FY26 | FY25 | %Change(YoY) |
|---|---|---|---|---|---|---|
| Total Revenue | 3,228 | 2,802 | 15% | 4,316 | 3,623 | 19% |
| Gross Profit | 1,629 | 1,438 | 13% | 2,403 | 2,289 | 5% |
| Gross Margin (%) | 50% | 51% | 56% | 63% | ||
| EBITDA | 351 | 299 | 17% | 525 | 523 | 0% |
| EBITDA Margin (%) | 11% | 11% | 12% | 14% | ||
| Depreciation | 10 | 10 | 3% | 39 | 38 | 4% |
| Finance Cost | 38 | 29 | 31% | 133 | 96 | 38% |
| Other Income | 19 | 18 | 8% | 78 | 47 | 65% |
| PBT (after adjustment of exceptional item) | 334 | 299 | 12% | 491 | 441 | 11% |
| Tax | 7 | 7 | 9% | 47 | 20 | 135% |
| Tax Rate (%) | 2.2% | 2.2% | 11% | 5% | 137% | |
| PAT for the Period (excluding extra ordinary items) | 327 | 292 | 12% | 384 | 416 | -8% |
| EPS | 17.18 | 15.37 | 12% | 23.42 | 22 | 6% |
Historical Financial Performance
The historical income statements and balance sheet for the company are provided in INR Mn:Historical Income Statement (Nath Bio-Genes' P&L Statement)
| Particulars | FY26 | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|
| Total Revenue | 4,316 | 3,623 | 3,326 | 3,013 | 2,783 |
| Gross Profit | 2,403 | 2,289 | 1,991 | 1,667 | 1,544 |
| Gross Margin (%) | 56% | 63% | 60% | 55% | 56% |
| EBITDA | 525 | 523 | 505 | 489 | 373 |
| EBITDA Margin (%) | 12% | 14% | 15% | 16% | 13% |
| Depreciation | 39 | 38 | 32 | 30 | 31 |
| Finance Cost | 133 | 96 | 91 | 101 | 106 |
| PBT (before exceptional) | 431 | 436 | 388 | 363 | 254 |
| Adjusted PAT | 384 | 416 | 367 | 352 | 215 |
| PAT Margin (%) | 9% | 11% | 12% | 12% | 9% |
| EPS | 23.42 | 22 | 21.6 | 18.5 | 11.3 |
Historical Balance Sheet (INR Mn)
This table presents key balances across the reported financial years:
| Assets | FY26 | FY25 | FY24 | FY23 | FY22 | Liabilities | FY26 | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 2,437 | 2,430 | 2,406 | 2,340 | 2,329 | Share Capital | 190 | 190 | 190 | 190 | 190 |
| Other Intangible Assets | 56 | 72 | 88 | 104 | 120 | Reserves & Surplus | 6,704 | 6,297 | 5,917 | 5,544 | 5,230 |
| Financial Assets | 268 | 61 | 61 | 51 | 51 | Long-Term Borrowings | 6 | 16 | 28 | 4 | 7 |
| Loans | 358 | 109 | Long-term Provisions | 49 | 35 | 30 | 28 | 26 | |||
| Other Non-current Assets | 426 | 442 | 421 | 225 | 218 | Short Term Borrowings | 1,212 | 1,095 | 1,055 | 1,048 | 923 |
| Inventories | 4,446 | 3,307 | 2,291 | 2,078 | 2,203 | Trade Payables | 1,305 | 787 | 421 | 277 | 551 |
| Trade Receivables | 838 | 888 | 943 | 973 | 879 | Other Current Liabilities | 1,340 | 1,735 | 1,112 | 830 | 482 |
| Cash & Bank Balances | 707 | 876 | 755 | 380 | 42 | Short Term Provisions | 23 | 12 | 18 | 9 | 11 |
| Loans & Advances | 1,620 | 1,665 | 1,629 | 1,711 | 1,502 | Total | 10,829 | 10,168 | 8,771 | 7,930 | 7,419 |
| Other Current Assets | 32 | 69 | 67 | 68 | 76 |
NATHBIOGEN Stock Price Movement
Shares of Nath Bio-Genes are edging higher to ₹162.67 as of 1:07 PM today, following a rally that gained 1.69% in live trading. The stock trades within its intraday range of ₹162.1 to ₹169.9 and has seen 81,543 shares traded so far.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.